Stay updated on Taletrectinib ROS1+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Taletrectinib ROS1+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Taletrectinib ROS1+ NSCLC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    A banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.
    Difference
    0.6%
    Check dated 2026-10-25T15:28:59.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov site revision changed from v3.7.1 to v3.7.2, with no visible change to the study record.
    Difference
    0.1%
    Check dated 2026-10-18T15:27:38.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.1%
    Check dated 2026-10-11T15:23:54.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    A new revision entry labeled v3.7.0 is added to the record history, and the previous revision v3.6.6 is removed from the displayed history.
    Difference
    0.1%
    Check dated 2026-09-20T19:44:04.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    A new revision label v3.6.6 has been added to the study's record history. The previous revision label v3.6.5 is removed from the changes shown in the history.
    Difference
    0.1%
    Check dated 2026-08-30T06:23:10.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    A new revision entry (v3.6.5) was added to the study history, signaling an updated version of the record for the trial (NCT04919811).
    Difference
    0.1%
    Check dated 2026-08-08T23:14:30.000Z thumbnail image

Stay in the know with updates to Taletrectinib ROS1+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Taletrectinib ROS1+ NSCLC Clinical Trial page.